MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Semagacestat

CAS No. : 425386-60-3

MCE 站：Semagacestat

产品活性：Semagacestat 是一种 γ-secretase 抑制剂，抑制 β-amyloid (Aβ42)，Aβ38 和 Aβ40，IC₅₀ 分别为 10.9，12 和 12.1 nM。也抑制 Notch，IC₅₀ 为 14.1 nM。Semagacestat 可用于阿尔茨海默病的相关研究。

研究领域：Neuronal Signaling  |  Stem Cell/Wnt

作用靶点：γ-secretase  |  Amyloid-β  |  Notch

In Vitro: Semagacestat (LY450139) reduces the secretion of Aβ42, Aβ40, and Aβ38 in 96-well-cultured media and increases β-CTF in cell lysates as expected, although this increase is unexpectedly attenuated at high concentrations.
In cortical neurons (CTX), Semagacestat (LY450139) causes a concentration-dependent decrease in Aβ40 secreted into the medium with IC₅₀ value 111 nM for Semagacestat. Semagacestat causes a concentration-dependent decrease in Aβ40 and Aβ42 secreted into the medium with an IC₅₀ value of 126 and 130 nM, respectively.
Semagacestat (3 Μm; for 4 days) exhibits no significant cell toxicity in Huh7 cells.

In Vivo: Semagacestat (LY450139) is found to decrease both Aβ42 and Aβ40 at 10 mg/kg (22-23% reduction;p<0.01) and increase β-CTF at 0.3-10 mg/kg in a dose-dependent manner (15-162% elevation; p<0.01 at 1-10 mg/kg). The γ-secretase inhibitor, Semagacestat (LY450139), a highly potent low molecular weight compound, significantly reduces β-amyloid (Aβ) levels in cell cultures permanently over-expressing APP and in both wildtype and transgenic APP-expressing mice. Three hours following p.o. dosing of 30 mg/kg Semagacestat levels of Aβ40 are reduced by 43% (unpaired t-test, p=0.002) in the brains of wildtype C57BL/6 mice compare with vehicle treated controls. Subcutaneous administration of Semagacestat (30 mg/kg) transiently decreases the amounts of Aβ40 in the dialysate with a maximum reduction in Aβ40 levels of 80% at 3 h post-dosing (p<0.001).

相关产品：Drug Repurposing Compound Library Plus  |  Clinical Compound Library Plus  |  Bioactive Compound Library Plus  |  Neuronal Signaling Compound Library  |  Stem Cell Signaling Compound Library  |  Wnt/Hedgehog/Notch Compound Library  |  Clinical Compound Library  |  Anti-Aging Compound Library  |  Drug Repurposing Compound Library  |  Differentiation Inducing Compound Library  |  Reprogramming Compound Library  |  Anti-COVID-19 Compound Library  |  Anti-Alzheimer’s Disease Compound Library  |  Anti-Breast Cancer Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Deferoxamine mesylate  |  DAPT  |  Valproic acid  |  β-Amyloid (25-35)  |  FPS-ZM1  |  Colivelin TFA  |  YO-01027  |  Rutin  |  LY-411575  |  β-Amyloid (1-42), human TFA  |  Compound E  |  CB-103  |  Tangeretin  |  Jagged-1 (188-204) (TFA)  |  20(S)-Ginsenoside Rg3  |  β-Amyloid (1-40)  |  Tolcapone  |  Geniposide  |  Ginsenoside Rg1  |  Licochalcone B  |  E 2012  |  IMR-1  |  β-Amyloid (1-42), rat TFA  |  L-685458  |  Carvacrol  |  Latrepirdine dihydrochloride  |  β-Amyloid (42-1), human  |  RBPJ Inhibitor-1  |  Dihydroergocristine mesylate

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。